StocksMedium•5 October 2026•
1 min read
Summit Partners with AstraZeneca and Daiichi for Cancer Therapy Trials
Key Facts
1Summit Therapeutics signed a deal with AstraZeneca and Daiichi Sankyo to study combinations of ivonescimab and Datroway.
2The clinical studies will focus on testing the combination's efficacy in breast and lung cancer treatments.
Summit Therapeutics signed a deal with AstraZeneca and Daiichi Sankyo to study combinations of ivonescimab and Datroway. Zacks reported that the clinical studies will focus on testing the combination's efficacy in breast and lung cancer treatments.
The partnership aims to broaden the clinical potential of ivonescimab by evaluating it alongside Datroway for oncology indications. Regarding related equity performance, AZN closed at $156.9 on October 2, 2026.